Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: Surgical and survival data

Annals of Surgical Oncology

Volumn 13, Issue 12, 2006, Pages 1717-1723

  Manci, Natalina ^a   Bellati, Filippo ^a   Muzii, Ludovico ^b   Calcagno, Marco ^a   Alon, Sagit Arbel ^a   Pernice, Milena ^a   Angioli, Roberto ^b   Panici, Pierluigi Bendetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Ovarian cancer recurrence; Secondary cytoreduction; Splenectomy

Indexed keywords

ANTHRACYCLINE; PACLITAXEL; PLATINUM BASED CHEMOTHERAPEUTIC AGENT; PLATINUM DERIVATIVE; TOPOTECAN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DISEASE DURATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; OVARY CANCER; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PROGNOSIS; RECURRENT DISEASE; REOPERATION; RETROSPECTIVE STUDY; REVIEW; SPLENECTOMY; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; FEASIBILITY STUDIES; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SPLENECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33845672203     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9048-2     Document Type: Review

References (31)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42:101-104.
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248-1259.
4. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Cain JM, Lewis JL Jr. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988; 159:1094-1098.
5. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave A. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
6. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88:144-153.
7. Munkarah A, Levenback C, Wolf JK, et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81:237-241.
8. Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34:334-338.
9. Chen LM, Leuchter RS, Lagasse LD, Karlan BY. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000; 77:362-368.
10. Carrington BM, Thomas NB, Johnson RJ. Intrasplenic metastases from carcinoma of the ovary. Clin Radiol 1990; 41:418.
11. Minagawa Y, Kanamori Y, Ishihara H, et al. Solitary metastatic ovarian carcinoma of the spleen: a case report. Asia Oceania J Obstet Gynaecol 1991; 17:45-48.
12. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 2004; 100:1152-1161.
13. Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79:344-349.
14. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20:1232-1237.
15. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21:2460-2465.
16. Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989; 64:1508-1513.
17. Deppe G, Zbella EA, Skogerson K, Dumitru I. The rare indication for splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 1983; 16:282-287.
18. Malfetano JH. Splenectomy for optimal cytoreduction in ovarian cancer. Gynecol Oncol 1986; 24:392-394.
19. Sonnendecker EW, Guidozzi F, Margolius KA. Splenectomy during primary maximal cytoreductive surgery for epithelial ovarian cancer. Gynecol Oncol 1989; 35:301-306.
20. Morris M, Gershenson DM, Burke TW, Wharton JT, Copeland LJ, Rutledge FN. Splenectomy in gynecologic oncology: indications, complications, and technique. Gynecol Oncol 1991; 43:118-122.
21. Nelson BE, Rose PG, Reale FR. Isolated parenchymal splenic metastasis in epithelial ovarian cancer. Gynecol Oncol 1993; 50:124-127.
22. Farias-Eisner R, Braly P, Berek JS. Solitary recurrent metastasis of epithelial ovarian cancer in the spleen. Gynecol Oncol 1993; 48:338-341.
23. Nicklin JL, Copeland LJ, O-Toole RV, Lewandowski GS, Vaccarello L, Havenar LP. Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1995; 58:244-247.
24. Balat O, Verschraegen C, Erbilen M, et al. Recurrence of ovarian cancer as a delayed solitary parenchymal splenic metastasis. Int J Gynecol Cancer 1996; 6:496-498.
25. Scarabelli C, Gallo A, Campagnutta E, Carbone A. Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma. Int J Gynecol Cancer 1998; 8:215-221.
26. Gemignani ML, Chi DS, Gurin CC, Curtin JP, Barakat RR. Splenectomy in recurrent epithelial ovarian cancer. Gynecol Oncol 1999; 72:407-410.
27. Lee SS, Morgenstern L, Phillips EH, Hiatt JR, Margulies DR. Splenectomy for splenic metastases: a changing clinical spectrum. Am Surg 2000; 66:837-840.
28. Lauro S, Trasatti L, Capalbo C, et al. Solitary splenic recurrence of epithelial ovarian cancer: a case report and review. Anticancer Res 2002; 22:3643-3645.
29. Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, Yuce K. The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14:51-56.
30. Chi DS, Abu-Rustum NR, Sonoda Y, et al. Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer. Gynecol Oncol 2006; 101:224-227.
31. Eisenkop SM, Spirtos NM, Lin WC. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 2006; 100:344-348.